Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-06-12 07:00 |
Biophytis annonce le succès du transfert industriel de production de BIO101 (2…
|
French | 192.0 KB | ||
| 2024-06-10 08:18 |
Biophytis announces filing of an IND application with the US FDA for its phase …
|
English | 195.1 KB | ||
| 2024-06-10 08:18 |
Biophytis annonce le dépôt d'une demande d'IND auprès de la FDA pour son étude …
|
French | 201.4 KB | ||
| 2024-06-07 08:23 |
Combined General Meeting of June 24, 2024
|
English | 307.2 KB | ||
| 2024-06-07 08:23 |
Assemblée générale mixte du 24 juin 2024
|
French | 313.1 KB | ||
| 2024-05-14 07:00 |
Biophytis announces the design of its phase 2 OBA clinical study in obesity
|
English | 193.5 KB | ||
| 2024-05-14 07:00 |
Biophytis annonce le design de son étude clinique de phase 2 OBA dans l'obésité
|
French | 189.5 KB | ||
| 2024-04-29 07:00 |
Biophytis is deploying its partnership strategy in obesity
|
English | 315.6 KB | ||
| 2024-04-29 07:00 |
Biophytis déploie sa stratégie de partenariat dans le domaine de l’obésité
|
French | 305.6 KB | ||
| 2024-04-24 23:00 |
Biophytis Announces Transfer of ADSs to OTC Market
|
English | 117.5 KB | ||
| 2024-04-24 23:00 |
Biophytis annonce le transfert de ses ADS sur le marché OTC
|
French | 177.9 KB | ||
| 2024-04-19 07:00 |
Biophytis announces ratio change under its American Depositary Receipt (“ADR”) …
|
English | 172.0 KB | ||
| 2024-04-19 07:00 |
Biophytis annonce un changement de ratio pour son programme d'American Deposita…
|
French | 308.8 KB | ||
| 2024-04-18 07:00 |
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical …
|
English | 335.3 KB | ||
| 2024-04-18 07:00 |
Biophytis annonce la création d'un Conseil Scientifique pour son étude clinique…
|
French | 335.4 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
